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This study is focused on the isolation and characterization of bioactive secondary metabolites from the ethanolic extract of stems of the Panamanian plant 
Talisia nervosa Radlk, through a series of target-based cellular assays related to the metabolic syndrome (MetS): a combination of type 2 Diabetes Mellitus 
(T2DM), hypercholesterolemia, inflammation, and obesity. Bioassay guided fractionation allowed the isolation of four known compounds: (–)-catechin (1), 
methyl gallate (2), ethyl gallate (3), and ß-D-glucopyranose,1,4,6-tris(3,4,5-trihydroxybenzoate) (4). This is the first report of (–)-catechin (1) and ß-D-
glucopyranose,1,4,6-tris (3,4,5-trihydroxybenzoate) (4) from T. nervosa. Among the isolates, 1 activated PPAR, but had no effect on PPAR. Compounds 2 - 
4 activated PPAR, PPAR and LXR. Interestingly, 2 was stronger than 3 towards all three targets. Methyl gallate (2) showed the most potent effect toward 
both PPAR and PPAR with an increase of 3.0 and 13-fold, respectively, while 4 was most potent in activating LXR with a fold induction of 5.3 at 
concentrations of 100 µg/mL.  The nitric oxide (NO) production was reduced by compounds 2 and 3 with IC50 values of 7.0 and 7.5 μg/mL, respectively. ß-D-
glucopyranose,1,4,6-tris (3,4,5-trihydroxybenzoate) (4) did not cause a significant increase in adipogenesis despite its strong PPARγ agonistic action (8.6-fold 
increase) and may represent a good candidate for the treatment of MetS without the undesirable side effect of weight gain.  
 




Metabolic syndrome (MetS) is a complex, progressive disorder that 
can develop over many years as a cluster of conditions characterized 
by a constellation of metabolic abnormalities, which include 
abdominal obesity, hyperglycemia, insulin resistance, atherogenic 
dyslipidemia and hypertension [1-2]. This devastating disease 
represents a public health concern and Latin American populations 
exhibit a higher prevalence of MetS than developed countries [3-4].  
 
Epidemiological studies have shown that MetS is associated with a 
greater risk of developing T2DM, cardiovascular disease (CVD) and 
stroke [5-6]. Due to the inter-connection between the multiple 
defects associated with MetS, there has been an increased interest in 
the molecular targets such as peroxisome proliferator-activated 
receptors (PPARs), liver X receptors (LXRs), nuclear factor-κB 
(NF-κB), and inducible nitric oxide synthase (iNOS) because of 
their close association with metabolic disorders such as T2DM, 
hypercholesterolemia, inflammation, and obesity. As a part of the 
inflammatory pathway, activation of NF-κB leads to insulin 
resistance and by blocking this pathway, insulin resistance and the 
resultant T2DM can be prevented [7]. In contrast, activators of 
PPAR and PPAR are effective in lowering blood lipids and 
glycemia, and have been considered useful in the treatment of 
obesity and diabetes [8]. LXR, in the same manner as the PPARs, 
suppresses production of inflammatory mediators in a manner 
reciprocal to its regulation of lipid metabolism [9]. Plant secondary 
metabolites affecting multiple targets are emerging as an important 
class of therapeutic agents. In fact, new anti-diabetic drugs that do 
not display undesirable side effects, such as hepatotoxicity, edema 
and weight gain, are in great demand. 
 
In our ongoing efforts to discover the potential of Panamanian flora 
as a source of bioactive molecules toward the cluster of metabolic 
disturbances, a screening of 75 plants against different molecular 
targets was carried out. The most active extract of Talisia nervosa 
Radlk (stems) was chosen for bioassay guided fractionation and 
isolation and identification of its bioactive constituents. T. nervosa, 
also called “mamón de monte”, belongs to the Sapindaceae family. 
This plant is distributed in the tropical moist forest and tropical wet 
forest of the Central and Caribbean parts of Panama. The pulp of this 
plant is edible and is consumed by Panamanian Choco Indians [10]. 
The genus Talisia contains diverse constituents such as catechins, 
flavonoids and hydroxycinnamic acids [11-12]. Previous chemical 
investigation of stems of T. nervosa in CIFLORPAN yielded ethyl 
gallate and methyl gallate, which showed weak antimalarial activity 
against chloroquine resistant strains of Plasmodium falciparum with 
IC50 of 35.3 μM and 38.0 μM, respectively [13]. 
 
Our preliminary evaluation showed that the ethanolic extract of T. 
nervosa exhibited dual activation of PPARα and PPARγ with an 
increase of 5.25 and 9.52-fold in PPARα and PPARγ activities 
compared with the control, at a concentration of 100 µg/mL, 
respectively (Table 1). Furthermore, the ethanolic extract also 
increased the insulin-stimulated glucose uptake and, unlike 
rosiglitazone, it did not cause significant increase in adipogenesis 
despite its PPARγ agonistic action, as shown in Figure 1. On the 
other hand, T. nervosa did not show inhibition of NF-κB, showing 
its specificity toward PPARs as the nuclear receptor targets. This 
plant extract also increased the LXR activity with an increase of 
1.5-fold, at a concentration of 50 µg/mL (Table 1). These data 
suggest that T. nervosa may play an important role in preventing 
MetS. 
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Table 1: Fold activation of PPARα, PPARγ and LXRα in HepG2 cells by the ethanolic 







Figure 1: Flow cytometric analysis of glucose uptake by T. nervosa in HepG2 cells (A). 
Effect of T. nervosa on adipocyte differentiation in 3T3-L1 cells by oil red O staining (B). 
 
In order to discover the active constituents, the ethanolic extract of 
stems of T. nervosa was successively partitioned with n-hexane, 
CHCl3, EtOAc, BuOH and H2O. This procedure generated five 
fractions which were subjected to bioassay guided fractionation. 
Their activities were monitored by a reporter gene assay for PPARα 
and PPARγ transcriptional activities.   
 
Among the 5 fractions, the EtOAc fraction was the most effective in 
increasing PPARα and PPARγ directed luciferase expression with 
6.5 and 7.5 fold increase at 100 µg/mL in comparison with the 
vehicle control, respectively. The other four fractions, hexane, 
CHCl3, BuOH and H2O, showed less activation of both PPARα and 
PPARγ signaling (an increase of 2.4, 2.2, 3.0, and 1.4-fold for 
PPARα, and 3.0, 1.8, 4.5 and 1.7-fold for PPARγ compared with the 
vehicle control, respectively).    
 
Bioassay guided fractionation of the EtOAc fraction led to the 
isolation of four known compounds: (–)-catechin (1, 9.5 mg), 
methyl gallate (2, 67.1 mg), ethyl gallate (3, 11.0 mg), and ß-D-
glucopyranose,1,4,6-tris(3,4,5-trihydroxybenzoate) (4, 5.3 mg). 
Their structures were elucidated by spectroscopic methods including 
1H NMR, 13C NMR, COSY, and HSQC, and by comparing with 
published spectral data [13]. 
 
Table 2: Inhibition of NF-κB in SW1353 cells and iNOS in RAW 264.7 cells and fold 
activation of PPARα, PPARγ, LXRα in HepG2 cells by compounds 1-4 from T. 
nervosa. 
 
aPositive control; NA: No activity. 
 
Out of 4 isolates, compound 2 (methyl gallate) showed the most 
potent effect toward both PPAR and PPAR with an increase of 
3.0 and 13-fold in their activity compared with the vehicle control, 
at a concentration of 100 µg/mL, respectively (Table 2). This 
compound has been previously isolated from T. nervosa and showed 
a weak in vitro antiplasmodial activity against Plasmodium 
falciparum and antileishmanial activity against Leishmania 
mexicana amastigotes [13]. However, this is the first report of 
compound 2 as a dual modulator of PPARα and PPARγ. On the 
other hand, the PPARα and PPARγ activations were followed by 
compounds 4 and 3 (an increase of 2.3 and 1.7-fold for PPARα, and 
8.6 and 4.6-fold for PPARγ compared with the vehicle control, at a 
concentration of 100 µg/mL, respectively) as shown in Table 2.  
 
The dual activation of PPARα and PPARγ exhibited by compound 4 
(a gallotannin) can be compared with the activity of another 
gallotannin 2,3,6-tri-O-galloyl-β-D-glucose reported earlier [14].  
Compound 1 [(–)-catechin] was less potent (1.2 and 2.0 fold 
activation for PPARα and PPARγ, respectively) compared with 
compounds 2, 3 and 4. It is consistent with a previous report that 
showed very weak activation of PPARα by catechin [15]. In 
addition, earlier studies have shown that catechin possesses a 
potential agonistic effect on PPARγ [16]. Our results are in 
agreement with previous reports and support the hypoglycemic 
effect of catechin mediated by PPARγ activation [17]. 
 
In order to evaluate whether the isolated compounds, acting as 
PPARγ agonists, also induce adipogenesis similar to rosiglitazone, 
their effect on adipocyte differentiation was examined on insulin-
stimulated 3T3-L1 adipocytes. A concentration-dependent increase 
in adipocyte differentiation was seen with compounds 2 and 3 as 
determined by oil red O staining (Figure 2). This result was 
consistent with the increase in lipid accumulation, determined by 
Nile Red fluorescent reagent. At the highest concentration of 50 
µg/mL, the lipid content of adipocytes was increased to 58% and 
68% by compounds 2 and 3, respectively, while rosiglitazone at a 
concentration of 3 µM increased adipogenesis by 100%, compared 
with the vehicle control. However, in a recent study, an inhibition of 
lipid accumulation in the early stages of adipogenesis by methyl 
gallate has been reported [18]. In contrast, compound 4 did not 
exhibit a significant increase in adipogenesis (Figure 2) despite its 
PPARγ agonistic action. This is similar to the effect of another 
gallotannin 2,3,6-tri-O-galloyl-β-D-glucose which did not enhance 
adipocyte differentiation in 3T3-L1 cells [14]. This suggests that 
compound 4 may represent as potential candidate for the treatment 
of MetS without the undesirable side effect of weight gain.   
 
 
Figure 2: Effect of compounds 2-4 on adipocyte differentiation in 3T3-L1 cells by oil red O 
staining. 
 
Subsequently, these compounds were also evaluated for NF-κB and 
iNOS inhibition, in order to investigate their anti-inflammatory 
potential. As a result, compound 1 did not show inhibition of 
phorbol 12-myristate 13-acetate (PMA) induced NF-κB activation, 
which is in agreement with the previous report related to the effect 
of catechin on NF-κB [19]. In addition, no inhibition of iNOS 
activity in LPS induced macrophages was seen, even though a weak 
effect of catechin on iNOS was reported earlier [20]. However, 
catechin has been shown to exhibit anti-inflammatory effects in 
100 50 25 100 50 25 100 50 25
(μg/mL) (μg/mL) (μg/mL)
Talisia nervosa  Radlk (Stem) 5.25 2.34 2.51 9.52 2.02 1.84 1.36 1.53 1.53
Ciprofibratea (30 μM) 3.09
Ciglitazone
a (30 μM) 5.88
25-hydroxycholesterol
a
 (25 μM) 3.04
Plant Species / Part
PPARα PPARγ LXRα 
        PPARα        PPARγ LXRα
IC50 IC50 100 50 25 100 50 25 100 50 25
(μg/mL) (μg/mL) (μg/mL)
1 NA NA 1.24 1.23 1.17 1.99 1.85 1.69 1.74 2.15 1.71
2 NA 7.0 3.05 1.23 1.18 13.0 3.02 1.83 3.16 1.99 1.99
3 NA 7.5 1.66 1.24 1.18 4.58 2.32 2.13 2.62 1.53 1.45
4 NA >50 2.26 1.33 1.25 8.62 2.31 2.37 5.32 2.12 1.49
Parthenolidea (μM)                      1.20 0.35
Ciprofibratea (30 μM) 3.31
Ciglitazonea (30 μM) 4.44
25-hydroxycholesterola (25 μM) 4.67
Compound
NF-κB    iNOS
(μg/mL)
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microglial cells by suppressing the production of pro-inflammatory 
mediators and mitigating NF-κB activity [21]. Furthermore, 
compounds 2 and 3 decreased the nitric oxide (NO) production in 
macrophages with IC50 values of 7.0 and 7.5 μg/mL, respectively 
(Table 2). These data are consistent with the previous studies, which 
reported that methyl gallate and ethyl gallate inhibited NO 
production and iNOS expression in macrophages stimulated by LPS 
[22-23]. On the other hand, these two compounds (2,3) did not show 
any inhibition of NF-κB in PMA induced chondrocytes, as shown in 
Table 2. 
 
The effect of these compounds on the activity of LXR was also 
evaluated. Compound 4 was the most effective with a 5.32 fold 
activation of LXRα at a concentration of 100 µg/mL, as shown in 
Table 2. At a concentration of 100 µg/mL, compounds 1, 2, and 3 
showed 1.74, 3.16, and 2.62-fold activation of LXRα, respectively. 
The results of molecular docking in an earlier study suggest 
catechin as a potential inhibitor of atherogenesis through activating 
LXR signaling [24]. 
 
 In conclusion, these compounds may have potential to work against 
metabolic disorders due to their effects on carbohydrate and lipid 




Plant material: Stems of T. nervosa were collected from National 
Park Altos de Campana, Buena Vista, Bejuco, Chame, Panama (N 
08o 41’ 27.2’’ W 079o 58’ 02.2’’) in January 2011 by botanist Alex 
Espinosa. Its taxonomic identity was established by Prof. Mireya D. 
Correa, at the Herbarium of the University of Panama (PMA), 
where the voucher specimen (Florpan No. 8735) is deposited. 
 
Extraction and isolation of active constituents: The dried 
powdered stems (1628 g) of T. nervosa were extracted exhaustively 
with 95% EtOH at room temperature for 24 h. After filtration, the 
solvent was removed in a rotary evaporator under reduced pressure 
to yield 86.5 g of crude dry extract, which was successively 
partitioned with n-hexane, CHCl3, EtOAc, BuOH and H2O. This 
procedure gave hexane (4.79 g), CHCl3 (2.81 g), EtOAc (18.38 g), 
BuOH (24.05 g) and H2O fractions (11.87 g).  The EtOAc fraction 
(10 g) was subjected to column chromatography using polyamide 
(50-160 µm, 310 g) with gradient elution using MeOH-H2O (1:1 → 
5:1) and MeOH-acetone (3:1 → 1:3). Fractions (20 mL) were 
collected and combined on the basis of their TLC profiles. 
Separated compounds were detected by UV before and after 
spraying with vanillin-H2SO4. The bioassay-guided fractionation for 
PPARα and PPARγ was monitored. The combined fractions were 
further separated on Sephadex LH-20 with MeOH (100%), which 
led to the isolation of: (–)-catechin (9.5 mg), methyl gallate (67.1 
mg), ethyl gallate (11.0 mg), and ß-D-glucopyranose,1,4,6-
tris(3,4,5-trihydroxybenzoate) (5.3 mg). 
 
PPARs and LXRα transcriptional activity: Activation of PPAR, 
PPAR and LXR was carried out following the method described 
previously, with some modification [14, 25]. Briefly, human 
hepatoma (HepG2) cells were cultured in DMEM supplemented 
with 10% FBS, 100 units/mL penicillin and 100 g/mL 
streptomycin. For the identification of PPAR and PPAR agonists, 
HepG2 cells were transfected with pSG5-PPAR and PPRE X3-tk-
luc or pCMV-rPPAR and pPPREaP2-tk-luc plasmid DNA (25 g 
of each/1.5 mL cell suspension), respectively, by electroporation at 
160 V for single 70 msec pulses using a BTX Square Electroporator 
T820. In a similar manner, cells were transfected with pCMX-
hLXRα and LXRE-tk-luc plasmid DNA, for the LXRα 
transcriptional activity. Transfected cells were plated at a density of 
5  104 cells/well in 96-well tissue culture plates and grown for 24 
h. After 24 h, the cells were treated with either test samples or 
positive controls (ciprofibrate, ciglitazone or 25(R)-hydroxyl-
cholesterol). After incubation for 24 h, the cells were lysed and the 
luciferase activity was measured. Light output was detected on a 
SpectraMax M5 plate reader. 
 
Adipocyte differentiation assay: Mouse embryo preadipocyte (3T3-
L1) cells were cultured in DMEM containing 10% FBS, 100 
units/mL penicillin and 100 μg/mL streptomycin. For the 
differentiation assay, preadipocytes were seeded in 48-well plates at 
a density of 2 x 104 cells/well and maintained until 2 days post-
confluence. After 2 days of confluence (day 0), medium was 
replaced with DMEM containing 10% FBS, 10 μg/mL insulin, 1 μM 
dexamethasone and test samples at various concentrations (12.5, 25 
and 50 μg/mL in case of pure compounds) or positive control 
rosiglitazone (3 μM). After 2 days, the medium was replaced with 
DMEM containing 10% FBS, 10 μg/mL insulin and test samples 
(day 4). Cells were then maintained in 10% FBS/ DMEM for an 
additional 4 days (day 8) [26]. The extent of adipogenesis was 
determined in differentiated adipocytes by quantification of lipid 
content and oil red O staining as described below. 
 
Quantification of lipid content in 3T3-L1 cells: Lipid content was 
estimated with an AdipoRed Assay Kit according to the 
manufacture’s protocol. On day 8 after differentiation in the 
presence of samples as described above, cells were carefully rinsed 
with 400 μL PBS. PBS (400 μL)  and 12 μL AdipoRed reagents 
were added to each well and the cells were incubated at 37°C for 10 
min. The fluorescent intensity was measured in a SpectraMax M5 
plate reader with excitation at 485 nm and emission at 572 nm. The 
percent lipid content of cells was calculated compared with the 
vehicle control (100%). 
 
Oil red O staining: In order to visualize the morphological changes, 
differentiated adipocytes were stained with Oil red O according to a 
previously described method, with some modification [27].  
Differentiated 3T3-L1 cells were rinsed twice with PBS and fixed 
with 70% ethanol for 30 min. The fixed cells were stained with Oil 
Red O solution (0.6% Oil Red O in isopropanol : water; 3:2) for 1 h 
at room temperature and washed twice with distilled water. The 
images of stained cells were captured by a Nikon DS-Ri1 camera 
attached to an Olympus IX50 microscope. 
 
NF-κB inhibition: Human chondrosarcoma (SW1353) cells were 
cultured as described earlier, with some modifications [28]. In brief, 
SW1353 cells were transfected with pBIIXLUC luciferase plasmid 
construct and plated in 96 well plates at a density of 1.25 x 105 
cells/well. After 24 h, the cells were exposed to different 
concentrations of pure compounds (1, 10, 100 µg/mL) or positive 
control parthenolide (0.125, 1.25, 12.5 M) for 30 min and then 
induced with 70 ng/mL of PMA for 8 h for the activation of NF-κB. 
Percent decrease in luciferase activity was calculated relative to the 
vehicle control (DMSO).  
 
iNOS inhibition: The assay was performed in mouse macrophage 
(RAW 264.7) cells, as described previously, with some modification 
[29]. RAW 264.7 cells were seeded at a density of 1  105 cells/well 
in 96-well plates and incubated for 24 h. After incubation, the cells 
were treated with either pure compounds or positive control 
(parthenolide) for 30 min. LPS (5 µg/mL) was added to induce the 
cells and the plates were incubated for 24 h. The activity of iNOS 
was determined by measuring the level of nitrite in the cell culture 
supernatant with Griess reagent. 
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